海普瑞早盘急速拉升,股价大涨24.94%,现报4.96港元,成交额8221.88万港元。海普瑞公布,公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,批准注射用H1710开展临床试验。据悉,H1710是公司自主研发的候选药物,公司具有H1710的全球开发及商业化权益。截至本公告日,于全球范围内尚无同一分子机制的同类产品上市。此外,海普瑞已于近日收到波兰卫生监督机构根据欧洲药品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.